戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 re for a PAR2 antagonist competing against a tethered ligand.
2 ond both to exogenous SFLLRN and to a second tethered ligand.
3 tivation of a chemokine receptor by a pseudo-tethered ligand.
4 by proteolysis of the N terminus to expose a tethered ligand.
5 s at a conserved target arginine to reveal a tethered ligand.
6 by proteolysis of the N terminus to reveal a tethered ligand.
7 red testisin specifically releases the PAR-2 tethered ligand.
8 MrgprC11 did not involve the generation of a tethered ligand.
9  proteolytic cleavage and the unmasking of a tethered ligand.
10 4 activation by both agonist peptide and the tethered ligand.
11 ytic cleavage, PAR(2) is activated through a tethered ligand.
12  by proteolytic cleavage and generation of a tethered ligand.
13 or 2 (PAR-2), via cleavage and exposure of a tethered ligand.
14 y cleavage of the amino terminus to unmask a tethered ligand.
15 tivated by proteolytic exposure of an occult tethered ligand.
16 placement of diffusible Netrin-B by membrane-tethered ligands.
17 ated by proteolytic shedding of its membrane-tethered ligands.
18  functionalized Au surfaces with three thiol-tethered ligands: 2-mercaptopropionic acid, 4-pyridinyle
19               These experiments suggest that tethered ligand activity is conferred in large part by t
20              SFLLRN-NH2, a thrombin receptor-tethered ligand analogue, and [3H]haTRAP exhibited compe
21 force-distance interaction between a polymer-tethered ligand and its receptor.
22 a gatekeeper for the interaction between the tethered ligand and LBS.
23 ward arrowT(57), which removed the canonical tethered ligand and prevented trypsin activation.
24 tially involved in interaction with both the tethered ligand and the soluble peptide agonist.
25 dicted an interaction between Gly48 from the tethered ligand and Thr153 from the LBS.
26 ins whose activity is controlled by flexibly tethered ligands and receptors.
27  the hexapeptide SFFLRN (that functions as a tethered ligand) and was blocked by the thrombin inhibit
28 the hexapeptide SF-FLRN (that functions as a tethered ligand) and was inhibited by hirudin.
29                                     Membrane-tethered ligands are recombinant proteins comprised of a
30 pecific labeling is achieved by presenting a tethered ligand at the synapses of genetically defined n
31  However, targeting PAR1 with an orthosteric-tethered ligand binding-site antagonist results in bleed
32  lithium compounds have been prepared with a tethered ligand, (CH(3)OCH(2)CH(2))(2)NCH(2)C(CH(3))(2)-
33                              More generally, tethered ligands competing with those free in solution a
34 ived agonist peptide (TRAP, a portion of the tethered ligand created by thrombin's proteolytic activi
35  a new amino terminus which then serves as a tethered ligand, docking intramolecularly to the body of
36 fication of the docking interactions between tethered ligand domain and receptor is critical for unde
37            Since peptides mimicking the PAR1 tethered ligand domain can also activate PAR2, we asked
38  of PAR1 antagonists, which compete with the tethered ligand domain rather than preventing PAR1 cleav
39                                          The tethered ligand domain shows a considerable degree of di
40                           Cleavage exposes a tethered ligand domain that binds to and activates the c
41 for thrombin, which is also activated by the tethered-ligand domain sequence (SFLLRN) and which promo
42 ast cells, and peptides corresponding to the tethered ligand domains of PAR-1 and PAR-2 increased [Ca
43  Synthetic "agonist peptides" that mimic the tethered ligand domains of thrombin receptor and PAR2 ac
44 ases cleave PARs at specific sites to expose tethered ligand domains that bind to and activate the cl
45         Catalytic groups are localized via a tethered ligand either to DNA or to tubulin, and red lig
46                               The novel PAR1-tethered ligand exposed by MMP-2 stimulates PAR1-depende
47 eptor-1 (PAR-1) can be activated by both the tethered ligand exposed by thrombin cleavage and a synth
48 ized complement component C5 and unmasks the tethered ligand for EC-expressed protease-activated rece
49 nerating a new amino terminus that acts as a tethered ligand for the receptor.
50                                 The distinct tethered ligands formed through cleavage of PAR1 by thro
51 tide (GYPGQV) representing the newly exposed tethered ligand from the amino terminus of PAR4 after pr
52         The protease-activated receptors are tethered ligand G protein-coupled receptors that are act
53 ity behavior would be expected for a matrix-"tethered" ligand; i.e., a ligand which acts from the mat
54 rin receptors dissociate streptavidin-biotin tethered ligands in focal adhesions within 60 min of cel
55                                   A membrane-tethered ligand-independent Notch1 construct also showed
56 equilibrium system the compound with the exo-tethered ligand inverts faster than its endo analog.
57  protease-activated receptor-1 (PAR-1) whose tethered ligand is generated by thrombin.
58 nd release from the cell surface of membrane-tethered ligands is an important mechanism of regulating
59 sis of interactions of proteins with surface-tethered ligands is introduced.
60 aved at an N-terminal arginine to unmask its tethered ligand, is generally regarded as a target for t
61 anchored Photoswitchable Orthogonal Remotely Tethered Ligand; maPORTL).
62 psin, SLIGRL-NH2 (corresponding to the PAR-2 tethered ligand), mast cell tryptase, and a filtrate of
63 s, we determined the molecular mechanism for tethered ligand-mediated PAR4 activation.
64 ns, we have explored the utility of membrane tethered ligands (MTLs).
65 c trypsin and a peptide corresponding to the tethered ligand of PAR-2, which is exposed by trypsin cl
66 rsibly to inhibit receptor activation by the tethered ligand of PAR1.
67 vation because peptides corresponding to the tethered ligand of the thrombin receptor were also able
68 eceptor-activating peptides derived from the tethered ligands of the PAR receptors.
69                                          The tethered ligand, once exposed, is always available to in
70 lasmin-cleavage sites removes the N-terminal tethered ligand or preligand, thereby providing an effec
71 let [Ca2+]i induced by alpha-thrombin or the tethered ligand peptide (TLP; SFLLRNPNDKYEPF) have been
72 s agonists for probing PAR function, but the tethered ligand peptide for PAR4, GYPGKF, lacks potency
73 o-terminal domain, but Ca2+ responses to the tethered ligand peptide SFLLRNPNDKYEPF were not affected
74 ie2, whereas thrombin and the canonical PAR3 tethered-ligand peptide did not.
75          APC, FXa, and the noncanonical PAR3 tethered-ligand peptide induced prolonged activation of
76                FXa and the noncanonical PAR3 tethered-ligand peptide induced Tie2- and PAR3-dependent
77                In vivo, the APC-derived PAR3 tethered-ligand peptide, but not the thrombin-derived PA
78                                         PAR3 tethered-ligand peptides beginning at amino acid 42, but
79                      Peptides that mimic the tethered ligand portion of the thrombin receptor have th
80 develop photoswitchable orthogonal, remotely-tethered ligands (PORTLs).
81 ontrol protein function: the photoswitchable tethered ligand (PTL) approach.
82 by binding covalently to the photoswitchable tethered ligand (PTL) retinal.
83                                Photoswitched tethered ligands (PTLs) can be used to remotely control
84                                Photoswitched tethered ligands (PTLs) have enabled fast and reversible
85 ceptors can be conjugated to photoswitchable tethered ligands (PTLs) to enable photoactivation, or ph
86 PAR2) is a 7-transmembrane G-protein-coupled tethered ligand receptor that is expressed by pancreatic
87 s to utilize mechanism(s) independent of its tethered ligand receptor to selectively prime phospholip
88                  These studies show that the tethered-ligand receptor mediates the GTPase activation
89 o the functioning G protein-linked thrombin (tethered ligand) receptor in human platelet membranes.
90 namics and the kinetics and spatial range of tethered ligand-receptor binding.
91 essions that relate key properties of single-tethered ligand-receptor interactions to multiple bond f
92 ligands that are distinct from the classical tethered ligand revealed by thrombin.
93 ated PAR1 and PAR2 bound to their endogenous tethered ligands, revealing a shallow and constricted or
94 by a small molecule mimicking the endogenous tethered ligand's interactions.
95 h sequences derived from these novel exposed tethered ligands, selectively stimulated PAR1-mediated m
96  cleavage and a synthetic peptide having the tethered ligand sequence (thrombin receptor agonist pept
97 nthetic agonist peptides (AP) that share the tethered ligand sequence also activate PAR2, often measu
98 ation of synthetic peptides derived from the tethered-ligand sequence.
99 ird residues of the human thrombin receptor "tethered ligand" sequence (SFLLR) led to a series of ago
100 vated by proteolytic-mediated exposure of a "tethered ligand" sequence and can also be activated by t
101 in the amino acid sequence of the receptors' tethered ligand sequences suggest that their respective
102 AP or SLIGRL-NH2, corresponding to the PAR-2 tethered ligand) stimulated both an 125I- efflux inhibit
103 d a decapeptide mimicking the Cat-S-revealed tethered ligand-stimulated PAR2 coupling to Galphas and
104 otency and constructed a series of synthetic tethered ligands (STLs).
105  as candidate therapeutics, we used membrane-tethered ligand technology.
106     Proteolytic cleavage of PAR(2) reveals a tethered ligand that activates PAR(2) and two major down
107 the extracellular domain of PAR1 generates a tethered ligand that activates PAR1 in an unusual intram
108  trypsin within the NH2-terminus, exposing a tethered ligand that binds and activates the receptor.
109  a new N-terminal domain that functions as a tethered ligand that binds intermolecularly to activate
110  their amino-terminal exodomains to unmask a tethered ligand that binds intramolecularly to the body
111 ls the receptor-activating motif, termed the tethered ligand that binds intramolecularly to the recep
112 )) at Arg(36) downward arrowSer(37) reveal a tethered ligand that binds to the cleaved receptor.
113 ough cleavage of the N-terminus, unmasking a tethered ligand that can then interact with the receptor
114 erating a new N terminus that functions as a tethered ligand that cannot diffuse away.
115 2) at R(36) downward arrowS(37) and reveal a tethered ligand that excites nociceptors, causing neurog
116 ctivating peptide (AP), corresponding to the tethered ligand that is exposed upon trypsin cleavage, a
117  major product of III-beta1a processing is a tethered ligand that may act as a cell surface signaling
118 ical site, exposing a previously undescribed tethered ligand that triggers biased G-protein agonism a
119 noncanonical sites, which result in distinct tethered ligands that activate G-protein signaling pathw
120 AR1 signaling and we describe a novel set of tethered ligands that are distinct from the classical te
121 ivated receptors (PARs) to expose N-terminal tethered ligands that bind and activate the cleaved rece
122 r extracellular amino terminus, revealing a 'tethered ligand' that self-activates the receptor.
123             Eph receptors and their membrane-tethered ligands, the ephrins, have important functions
124 gamma-thrombin, which does not stimulate the tethered ligand thrombin receptor and caused little or n
125                                          The tethered-ligand thrombin receptor appeared to mediate th
126          Using the characteristic time for a tethered ligand to bind to a surface receptor, we study
127 volving sequestration or modification of the tethered ligand to prevent or terminate its function.
128  or peptidomimetics can mimic binding of the tethered ligand to stimulate signaling without the nonsp
129 ar surface of PAR2, preventing access of the tethered ligand to the peptide-binding site.
130                      In this population, the tethered ligand unmasked by thrombin cleavage must not b
131          However, the distinct non-canonical tethered ligands unmasked by neutrophil elastase and pro
132 hereby exposing a new N-terminal sequence, a tethered ligand, which initiates a cascade of molecular
133            Trypsin cleaves PAR-2 to expose a tethered ligand, which irreversibly activates the recept
134 the protease-mediated "shedding" of membrane-tethered ligands, which then activate EGFRs.
135 nt the interaction of the protease-generated tethered ligand with the body of the receptor.
136 s retained efficacy against both soluble and tethered ligands with lower cLogP values and an increase

 
Page Top